Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2020 | 177Lu-PSMA-617 vs. cabazitaxel for mCRPC

Michael Hofman, MD, Peter MacCallum Cancer Centre, Melbourne, Australia, discusses a randomised phase II trial (NCT03392428) of investigating a 177Lu-PSMA-617 (LuPSMA) theranostic versus cabazitaxel in metastatic castration resistant prostate cancer (mCRPC). This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).